Status:
UNKNOWN
Acute Encephalopathy in Critically Ill Patients With COVID-19
Lead Sponsor:
Ictal Group
Conditions:
COVID-19
Encephalopathy
Eligibility:
All Genders
18+ years
Brief Summary
Infection with SARS-CoV-2 or severe acute respiratory syndrome coronarvirus type 2 was highlighted in December 2019 in the city of Wuhan in China, responsible for an pandemic evolution since March 11,...
Detailed Description
All patients with SARS-CoV-2 infection and acute encephalopathy at presentation will be prospectively included in the NEURO-COVD-19 study. This study will collect demographic data, clinical examen at ...
Eligibility Criteria
Inclusion
- Critical/Intensive care or Neurocritical care admission
- Admission for/with acute encephalopathy defined as a rapidly developing (over less than 4 weeks, but usually within hours to a few days) pathobiological process in the brain; including delirium or subsyndromal (DSM V definition) or coma (Glasgow coma scale score \< 9)
- SARS-COV-2 infection (respiratory or other PCR specimen)
- Age ≥ 18 years
Exclusion
- \- Opposition to study participation from the patient itself or patient surrogate
Key Trial Info
Start Date :
March 23 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2020
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT04320472
Start Date
March 23 2020
End Date
December 31 2020
Last Update
October 22 2020
Active Locations (39)
Enter a location and click search to find clinical trials sorted by distance.
1
Jackson Memorial Health System; University of Miami, Miller School of Medicine
Miami, Florida, United States, 33136
2
Wellstar Atlanta Medical Center
Atlanta, Georgia, United States, 30312
3
Universidade Federal de São Paulo
São Paulo, Brazil
4
Fundación Valle del Lili, University Hospital
Cali, Colombia